Europe Biodefense Market to Grow at a CAGR of 8.8% to reach US$ 1,286.58 Million from 2020 to 2027

Europe Biodefense Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product (Anthrax, Small pox, Botulism, Radiation/Nuclear, Others), and Geography

  • Report Code : TIPRE00010410
  • Category : Biotechnology
  • Status : Published
  • No. of Pages : 105
Buy Now

Europe Biodefense Market to Grow at a CAGR of 8.8% to reach US$ 1,286.58 Million from 2020 to 2027

Buy Now

The Europe Biodefense market is expected to reach US$ 1,286.58 Mn in 2027 from US$ 2,516.91 Mn in 2019. The market is estimated to grow with a CAGR of 8.8% from 2019-2027.

The growth of the Biodefense market is driven by factors such as the favorable government initiatives increase in the number of naturally occurring outbreaks, increasing threat of biological weapons and nuclear armed ICBM in the Europe region. However, fluctuations in funding due to changing EU is likely to restrain the market growth to a certain extent.

Biodefense is referred to the measures taken to restore biosecurity of a group of organisms that are, or may be, subject to biological threats or infectious diseases. It is an effective public health care system with strong disease surveillance and rapid actions designed to counter biological threats, to limit the spread of disease and provide surge medical care.

Disease outbreaks are usually caused by an infection, transmitted through person-to-person contact, animal-to-person contact, or from the environment or other media. Emerging infectious diseases are infections that have recently appeared within a population and are rapidly increasing or threaten to grow shortly. The World Health Organization warned in its 2007 report that infectious diseases are emerging at a rate that has not been seen before. Since the 1970s, about 40 infectious diseases have been discovered, including SARS, MERS, Ebola, chikungunya, avian flu, swine flu, zika, and most recently, coronavirus. In May through June 2011, a novel strain of Escherichia coli O104:H4 bacteria caused a significant outbreak of foodborne disease focused in northern Germany. In total, there were 3,950 people affected and 53 died, 51 of whom were from Germany. 800 people suffered from hemolytic uremic syndrome (HUS), which would lead to kidney failure. The growing prevalence of Ebola and Zika virus infections is also likely to contribute to the Biodefense market development. Due to coronavirus outbreak, As of 15 April, there have been 98,476 confirmed cases of COVID-19 in the UK, and 12,868 people with confirmed infection have died. Further, on March 18, 2020 Emergent BioSolutions signed development and manufacturing agreement with Vaxart for their experimental oral vaccine candidate for Coronavirus Disease.

The release of pathogenic agents such as anthrax or smallpox, biological toxins, chemical weapons such as nerve gas, or radioactive substances caused public threats in the past. In order to prevent such outbreaks, the government has planned various strategies. The growing prevalence of infectious diseases, such as coronavirus, Ebola and zika virus, is likely to boost the investments in the field of biodefense, thereby driving the Biodefense market growth.

Biological weapons (BWs) deliver toxins and microorganisms, such as viruses and bacteria, so as to intentionally inflict disease among people, animals, and agriculture. Biological attacks can result in destruction of crops, temporarily discomforting a small community, killing large numbers of people, or other outcomes. Biological weapons have a long history of use. In 1346, the invading Tartar army catapulted the bodies of plague victims into the Crimean Peninsula city of Kaffa and infected its citizens. In 1763, British troops under General Jeffrey Amherst gave the Delaware Indians blankets used by people with smallpox, possibly infecting the susceptible native population. Although recent advances in biotechnology have made it easier to develop dangerous viruses, bacteria, and toxins with fewer resources. This has increased concerns that individuals and groups could resort to bioterrorism to attack a population.

Moreover, due to factors such as increasing border threats, rising national security concerns, and changing dynamics of warfare, countries such as Russia, UK in Western Europe are inclined towards enhancing their missile weapon store. They are also modernizing their old missiles with the new propulsion system and warheads. Hence, as the threat for biological weapon and nuclear armed ICBM is increasing, governments of various countries are actively funding for biodefense, thereby, positively propelling the European market.

Rest of Europe Biodefense market Revenue and Forecasts to 2027 (US$ Bn)

Rest of Europe Biodefense market Revenue and Forecasts to 2027 (US$ Bn)
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

EUROPE BIODEFENSE MARKET – MARKET SEGMENTATION

Europe Biodefense Market – By Product

  • Anthrax
  • Small pox
  • Botulism
  • Radiation/Nuclear
  • Others

Europe Biodefense Market – By Country

  • United Kingdom
  • Germany
  • France
  • Spain
  • Italy

Companies Mentioned

  • Bavarian Nordic
  • Alnylam Pharmaceuticals, Inc.
  • SIGA Technologies
  • Emergent BioSolutions Inc.
  • Cleveland Bio Labs
  • Dynavax Technologies
  • Elusys Therapeutics, Inc.
  • Soligenix
  • Altimmune
  • Pluristem Therapeutics
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Product, and Geography

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

UK, Germany, France, Italy, Russia

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Europe Biodefense market – By Product

1.3.2 Europe Biodefense market – By Country

2. Europe Biodefense Market – Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Europe Biodefense market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 Biodefense market - Europe PEST Analysis

4.3 Expert Opinion

5. Europe Biodefense Market - Key Market Dynamics

5.1 Key Market Drivers

5.1.1 Presence of Favourable Government Initiatives

5.1.2 Increase in the Number of Naturally Occurring Outbreaks

5.1.3 Increasing Threat of Biological Weapons and Nuclear Armed ICBM

5.2 Key Market Restraints

5.2.1 Fluctuations in funding due to the changing EU & government policies

5.3 Key Market Opportunities

5.3.1 Increased Adoption of Technologies

5.4 Future Trends

5.4.1 Predictive Analytics to Reshape Biodefense Market

5.5 Impact Analysis

6. Biodefense Market – Europe Analysis

6.1 Europe Biodefense Market Revenue Forecasts and Analysis

7. Europe Biodefense market Analysis And Forecasts To 2027 – By Product

7.1 Overview

7.2 Europe Biodefense market, By Product 2019 & 2027 (%)

7.2.1 Europe Biodefense market Revenue and Forecasts to 2027, By Product (US$ Mn)

7.3 Anthrax

7.3.1 Overview

7.3.2 Europe Anthrax Market Revenue and Forecast to 2027 (US$ Mn)

7.4 Small pox

7.4.1 Overview

7.4.2 Europe Small Pox Market Revenue and Forecasts to 2027 (US$ Mn)

7.5 Botulism

7.5.1 Overview

7.5.2 Europe Botulism Market Revenue and Forecasts to 2027 (US$ Mn)

7.6 Radiation/Nuclear

7.6.1 Overview

7.6.2 Europe Radiation/Nuclear Market Revenue and Forecasts to 2027 (US$ Mn)

7.7 Others

7.7.1 Overview

7.7.2 Europe Others Market Revenue and Forecasts to 2027 (US$ Mn)

8. Biodefense market Revenue and Forecasts To 2027 – Geographical Analysis

8.1 Europe Biodefense market Revenue and Forecasts To 2027

8.1.1 Overview

8.1.2 Europe: Biodefense Market - Revenue and Forecast to 2027 (USD Million)

8.1.3 Europe: Biodefense Market, by Product, 2018–2027 (USD Million)

8.1.4 Europe: Biodefense Market, by Country, 2018 & 2027 (%)

8.1.5 Germany: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.5.1 Germany: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.5.2 Germany: Biodefense Market, by Product Type, 2018–2027 (USD Million)

8.1.6 UK: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.6.1 UK: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.6.2 UK: Biodefense Market, by Product Type, 2018–2027 (USD Million)

8.1.7 France: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.7.1 France: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.7.2 France: Biodefense Market, by Product Type, 2018–2027 (USD Million)

8.1.8 Spain: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.8.1 Spain: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.8.2 Spain: Biodefense Market, by Product Type, 2018–2027 (USD Million)

8.1.9 Italy: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.9.1 Italy: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.9.2 Italy: Biodefense Market, by Product Type, 2018–2027 (USD Million)

9. Impact 0f Covid-19 Pandemic On Europe Biodefense Market

9.1 Europe: Impact assessment of COVID-19 Pandemic

10. Europe Biodefense market Industry Landscape

10.1 Overview

10.2 Growth Strategies in The Biodefense Market, 2016-2020

10.3 Inorganic Growth Strategies

10.3.1 Overview

10.4 Organic Growth Strategies

10.4.1 Overview

11. Company Profiles

11.1 Bavarian Nordic

11.1.1 Key Facts

11.1.2 Business Description

11.1.3 Products and Services

11.1.4 Financial Overview

11.1.5 SWOT Analysis

11.1.6 Key Developments

11.2 Alnylam Pharmaceuticals, Inc.

11.2.1 Key Facts

11.2.2 Business Description

11.2.3 Products and Services

11.2.4 Financial Overview

11.2.5 SWOT Analysis

11.2.6 Key Developments

11.3 SIGA Technologies

11.3.1 Key Facts

11.3.2 Business Description

11.3.3 Products and Services

11.3.4 Financial Overview

11.3.5 SWOT Analysis

11.3.6 Key Developments

11.4 Emergent BioSolutions Inc.

11.4.1 Key Facts

11.4.2 Business Description

11.4.3 Products and Services

11.4.4 Financial Overview

11.4.5 SWOT Analysis

11.4.6 Key Developments

11.5 Cleveland Bio Labs

11.5.1 Key Facts

11.5.2 Business Description

11.5.3 Products and Services

11.5.4 Financial Overview

11.5.5 SWOT Analysis

11.5.6 Key Developments

12. Appendix

12.1 About The Insight Partners

12.2 Glossary of Terms


LIST OF TABLES

Table 1. Europe Biodefense market Revenue and Forecasts To 2027, By Product (US$ Mn)

Table 2. Europe Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 3. Germany Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 4. UK Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 5. France Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 6. Spain Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 7. Itlay Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 8. Recent Inorganic Growth Strategies In The Biodefense Market

Table 9. Recent Organic Growth Strategies In The Biodefense Market

Table 10. Glossary of Terms, Biodefense Market


LIST OF FIGURES

Figure 1. Biodefense market Segmentation

Figure 2. Europe Biodefense market Overview

Figure 3. Anthrax Segment Held Largest Share of Product Segment in Biodefense Market

Figure 4. Germany is Expected to Show Remarkable Growth During the Forecast Period

Figure 5. Europe Biodefense market- Leading Country Markets (US$ Mn)

Figure 6. Europe Biodefense market, Industry Landscape

Figure 7. Biodefense market - Europe PEST Analysis

Figure 8. Biodefense market Impact Analysis of Drivers and Restraints

Figure 9. Europe Biodefense market – Revenue Forecasts and Analysis – 2019- 2027

Figure 10. Europe Biodefense market, By Product 2019 & 2027 (%)

Figure 11. Europe Anthrax Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 12. Europe Small Pox Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 13. Europe Botulism Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 14. Europe Radiation/Nuclear Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 15. Europe Others Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 16. Europe: Biodefense Market, by Key Country – Revenue (2019) (USD Million)

Figure 17. Europe Biodefense Market Revenue and Forecast to 2027 (USD Million)

Figure 18. Europe: Biodefense Market, by Country, 2018 & 2027 (%)

Figure 19. Germany: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

Figure 20. UK: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

Figure 21. France: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

Figure 22. Spain: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

Figure 23. Italy: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

Figure 24. Impact Of Covid-19 Pandemic In European Country Markets

Figure 25. Growth Strategies in the Biodefense Market, 2016-2020

The List of Companies - Europe Biodefense Market

  1. Bavarian Nordic
  2. Alnylam Pharmaceuticals, Inc.
  3. SIGA Technologies
  4. Emergent BioSolutions Inc.
  5. Cleveland Bio Labs
  6. Dynavax Technologies
  7. Elusys Therapeutics, Inc.
  8. Soligenix
  9. Altimmune
  10. Pluristem Therapeutics

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Biotechnology : READ MORE..